Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond

Commonly observed aberrations in epidermal growth factor receptor (EGFR) signaling have led to the development of EGFR-targeted therapies for various cancers, including non–small cell lung cancer (NSCLC). EGFR mutations and overexpression have further been shown to modulate sensitivity to these EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaney, Christopher, Frank, Samuel, Huang, R Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593375/
https://www.ncbi.nlm.nih.gov/pubmed/25962919
http://dx.doi.org/10.1186/s40880-015-0007-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593375/
https://www.ncbi.nlm.nih.gov/pubmed/25962919
http://dx.doi.org/10.1186/s40880-015-0007-9

Ejemplares similares